

## **Memphasys Executes exclusive significant value 12 Month National Supply Agreement with Monash IVF Group for Felix™ System**

### **Highlights**

- **Agreement follows long term collaboration, culminating in Monash IVF conducting the pivotal Felix™ clinical trial concluded in 2025**
- **12-month exclusive National Supply Agreement executed between Memphasys and Monash IVF for the Felix™ automated sperm selection system**
- **Significant value contract, with pathway to expansion and recurring revenue model**
- **Felix™ cartridges and consoles to be supplied across Monash IVF's Australian clinic network, currently 22 clinics across all mainland capital cities**
- **Monash conducted 12,085 IVF cycles in 2025 with the majority being Intracytoplasmic Sperm Injection (ICSI)**
- **Initial rollout to commence at two Monash IVF Group clinics, with successful completion triggering national deployment across the Monash IVF network and commencement of the 12-month supply agreement**
- **Monash IVF anchor customer deployment provides reference site validation, pathway for market expansion, and de-risks Australian commercialisation strategy**

Memphasys Limited (ASX: MEM), an Australian-based reproductive biotechnology company, and Monash IVF Group Limited (ASX: MVF), one of Australia's largest ART providers, have entered into a 12-month exclusive national Supply Agreement for the Felix™ System in Australia.

The execution of the agreement follows Memphasys securing inclusion in the Australian Register of Therapeutic Goods (ARTG) for the Felix™ System, enabling immediate commercial deployment across Australia.

The agreement marks a significant commercial and clinical milestone in a partnership that has spanned more than a decade, reflecting a shared commitment to advancing reproductive medicine through rigorous scientific validation and scalable clinical application.

### **Scope of the Supply Agreement**

Monash IVF Group is one of Australia's largest fertility providers, with an established network of clinics and laboratories across Australia and Asia. In FY2025, Monash IVF reported 12,085 stimulated IVF cycles and approximately 21% share of the Australian stimulated IVF market, underscoring its scale and significance within the assisted reproductive technology sector. The Group's extensive clinical footprint provides access to a substantial patient population and positions it as a leading provider of fertility services in the Asia-Pacific region.

The agreement commences with an initial three-month roll-out phase, during which Felix™ will be deployed across two designated sites. This phase will include implementation, staff training, system troubleshooting and collection of outcome data across embryology and clinical metrics. Upon successful completion of this initial roll-out phase, the full 12-month supply term will commence, enabling national rollout of Felix™ across Monash IVF's clinic network, comprising 22 clinics located across all mainland capital cities.

### **Commercial Terms and Initial Commitments**

The commercial terms of the agreement are commercially sensitive and remain confidential. Subject to successful completion of the initial three-month rollout phase and final site confirmation, the agreement is expected to support significant ongoing revenue generation through the supply of Felix™ cartridges and consoles.

The agreement constitutes the largest commercial arrangement entered into by Memphasys for Felix™ to date and represents a significant step in the Company's transition from product validation to scaled commercial deployment. Initial delivery of cartridges and consoles is expected to commence immediately as part of the rollout phase.

### **Financial Impact and Revenue Visibility**

The agreement provides Memphasys with clear revenue visibility over the initial 12-month term. It establishes a significant value commitment over the initial term, representing the potential for baseline recurring revenue from a major institutional customer.

Importantly, the quarterly ordering schedule enables predictable production planning and cash flow visibility. The agreement's performance review framework and good-faith extension negotiations provide a pathway for expansion beyond the initial 12-month term, with potential for increased volume as Felix™ adoption expands across Monash IVF's clinic network and to other Australian ART providers in the future.

### **Operational Readiness and Manufacturing Capacity**

Memphasys has established the manufacturing capacity, supply chain infrastructure and quality systems required to support the Monash IVF agreement and future growth opportunities. With TGA-approved manufacturing processes in place, the Company is well positioned to scale production to meet increasing demand from both existing and prospective customers.

On the agreement Marjan Mikel, Chair of the Commercialisation Committee at Memphasys, commented:

*"Executing this agreement with Monash IVF is a significant commercial milestone for Memphasys, validating both the clinical value of Felix™ and our commercialisation strategy. Beyond the contracted revenue opportunity, Monash IVF provides a world-class reference customer and a strong platform to support broader adoption of Felix™ across Australia and international markets."*

## **Decade-Long Collaboration Culminates in Pivotal Clinical Trial**

The execution of the Supply Agreement follows the successful completion of a pivotal, multi-site clinical trial conducted by Monash IVF, which concluded in 2025 and confirmed the Felix™ System's best-in-class performance in sperm selection<sup>1</sup>.

The trial represents the culmination of a long term scientific, technical and clinical collaboration between Memphasys and Monash IVF Group, advancing Felix™ from concept to large-scale clinical validation within a leading IVF network. The parties expect the trial outcomes to be published in the near future, providing further independent clinical validation of the significant benefits Felix™ offers over conventional sperm selection methods and supporting broader commercial adoption in Australia and international markets.

## **Market Opportunity and Commercial Significance**

Australia represents a strategically important market for Felix™ commercialisation, with more than 60,000 fresh IVF cycles performed annually. Monash IVF Group operates 22 clinics representing one of Australia's largest integrated clinic networks, positioning this agreement as a significant anchor customer deployment.

This agreement further expands Memphasys' commercial footprint, with Felix™ now positioned across Australia, Europe, the Middle East and North Africa, India, Japan and South East Asia. As one of the most respected IVF providers in the region, Monash IVF provides Memphasys with a globally recognised reference customer whose clinical reputation is expected to support broader adoption of Felix™ in both existing and new markets. Based on the Company's recent track record of converting commercial opportunities into signed agreements, Memphasys expects to secure additional contracts in the near term, further expanding its international presence and accelerating the global rollout of Felix™.

## **Authorised by the Board of Memphasys Limited.**

Ends

For further information, please contact:

Colin Jacoby  
Chapter One Advisors  
E: [cjacoby@chapteroneadvisors.com.au](mailto:cjacoby@chapteroneadvisors.com.au)

## **About Memphasys**

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

---

<sup>1</sup> Refer ASX announcement dated 24 March 2025

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: [www.memphasys.com](http://www.memphasys.com)

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

### **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys's current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Memphasys, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Memphasys cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Memphasys will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.